The Intra-Drug Eluting Stent (DES) Restenosis Study

Phase 4

Completed

• Conditions: Coronary Artery Disease
• Interventions: Device: drug-eluting stent and balloon angioplasty; Device: drug-eluting stent

• Registration Number: NCT00323895
• Lead Sponsor: Cordis Corporation

Brief Summary

A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.

Detailed Description

This is a prospective, randomized study to be conducted at up to 33 sites in France with 3 groups of patients (1 group with intra-Taxus™ restenosis, 1 group with intra-Cypher™ restenosis and 1 control group with intra-BMS restenosis). All patients will have a repeat angiography at 9 to 12 months post-procedure and will be followed up to 12 months post-procedure.

Study Timeline

• Study Start: 2006-03
• Study First Submitted: 2006-05-09
• Study First Submitted QC: 2006-05-09
• Study First Posted: 2006-05-10
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-28
• Last Update Posted: 2010-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

• Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
• Patient has an intra-DES (TAXUS™ OR CYPHER™) or intra-BMS restenosis of >= 50% and <100% (by QCA online of the MLD compared to the distal reference diameter) in a native coronary artery;
• Study target lesion must be located in a restenotic native coronary artery >=2.25mm and <=3.5mm in lumen diameter and <=30mm in length by visual estimate and within a region up to 5mm to the proximal/distal stent edge;
• Study target lesion must have undergone coronary interventional treatment >= 4 weeks previously. Patients with one ore more prior PTCA procedures at the target lesion are acceptable candidates.
• Study target lesion can not be located in a vessel containing another lesion requiring treatment. Lesions located in other vessels may be treated with percutaneous revascularization at the time of the procedure, BUT they must be successfully treated prior to the treatment of the study target lesion;
• Patient is candidate for a current percutaneous revascularisation technique;
• Patient is willing to comply with the specified follow-up evaluations (including angiographic follow-up);
• Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee;

Exclusion Criteria

• Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK >2 times normal within the preceding 72 hours and the CK enzymes remain above normal at the time of treatment;
• Has unstable angina classified as Braunwald A I-II-III;
• Unprotected left main coronary disease with ³50% stenosis;
• Significant (>50%) stenoses of additional lesions proximal or distal to the target lesion(s) that might require revascularization or impede runoff;
• Target lesion is in an internal mammary artery, saphenous vein bypass graft or is located in the left main or is ostial;
• Stent implantation(s) is a non-elective, emergency procedure;
• Stent at the target restenosed lesion is neither TAXUS™ , CYPHER™ DES nor a BMS;
• Documented left ventricular ejection fraction <=25%;
• Totally occluded vessel (TIMI 0 level).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	drug-eluting stent and balloon angioplasty	group with intra-Cypher™ restenosis
2	drug-eluting stent and balloon angioplasty	group with intra-Taxus™ restenosis
3	drug-eluting stent	group with intra-BMS restenosis

Primary Outcome Measures

Name	Time	Method
In stent late loss.	between 9 - 12 months

Secondary Outcome Measures

Name	Time	Method
In-stent, in-segment, and in-lesion binary restenosis rate by QCA.	between 9 - 12 months
In-lesion late loss as assessed by QCA.	between 9 - 12 months
In-stent and in-lesion MLD, and percent diameter stenosis (%DS) as assessed by QCA.	between 9 - 12 months
Target lesion revascularization (TLR).	30 days, 6 and 12 months
Target vessel revascularization (TVR).	30 days, 6 and 12 months
Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization.	30 days, 6 and 12 months
Composite of Major Adverse Cardiac Events (MACE) defined as cardiac death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization.	30 days, 6 months and 12 months

Trial Locations

Locations (2)

Centre Cardiologique du Nord; 🇫🇷 Saint Denis, France

Unite de Cardiologie Interventionelle; 🇫🇷 Toulouse Cedex 3, France